Sample Name
Sample Code
Sample Name
Sample Code
Sample Name
Sample Code
4
Cars.com
CARS
5
Constellation Brands
STZ
US OptionsDetailed Quotes
BCAX250417P35000
- 0.00
- 0.000.00%
15min DelayClose Apr 8 09:30 ET
0.00High0.00Low
0.00Open0.00Pre Close0 Volume0 Open Interest35.00Strike Price0.00Turnover0.00%IV-273.53%PremiumApr 17, 2025Expiry Date25.63Intrinsic Value100Multiplier8DDays to Expiry0.00Extrinsic Value100Contract SizeAmericanOptions Type--Delta--Gamma0.37Leverage Ratio--Theta--Rho--Eff Leverage--Vega
Bicara Therapeutics Newsroom
H.C. Wainwright Maintains Bicara Therapeutics(BCAX.US) With Buy Rating, Cuts Target Price to $44
Express News | HC Wainwright & Co. Maintains Buy on Bicara Therapeutics, Lowers Price Target to $44
New Analyst Forecast: $BCAX Given $48.0 Price Target
TD Cowen Maintains Bicara Therapeutics(BCAX.US) With Buy Rating
Promising Data and Durable Responses Drive Buy Rating for Bicara Therapeutics
Morgan Stanley Maintains Bicara Therapeutics(BCAX.US) With Buy Rating, Maintains Target Price $36
Bicara Therapeutics Reports Strong Financial Position and Clinical Progress
Stifel Maintains Bicara Therapeutics(BCAX.US) With Buy Rating, Raises Target Price to $48
Bicara Therapeutics | 10-K: FY2024 Annual Report
Bicara Therapeutics Price Target Raised to $48 From $47 at Stifel
Bicara Therapeutics | 8-K: Bicara Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update
Bicara Therapeutics: $490M in Cash and Cash Equivalents Expected to Fund Ops Into the 1H of 2029 >BCAX
Bicara Therapeutics 4Q Loss $21M >BCAX
Bicara Therapeutics 4Q Loss/Shr 39c >BCAX
Press Release: Bicara Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update
12 Health Care Stocks Moving In Tuesday's After-Market Session
Bicara Therapeutics Announces Upcoming Presentations at AACR Annual Meeting 2025
Express News | Cantor Fitzgerald Reiterates Overweight on Bicara Therapeutics, Maintains $13.01 Price Target
We Think Bicara Therapeutics (NASDAQ:BCAX) Can Afford To Drive Business Growth
Bicara Therapeutics Management to Meet With Cantor Fitzgerald
Market Insights
Discussing
Chinese stock earnings surge: Will profit sustain the rally?
1. Which sectors are likely to be market highlights this season? 2. With the government's emphasis on technological innovation and sustaina
Moomoo News Global
Mar 4 23:26
China's Two Sessions: Key Takeaways on Stock Price Movements Before and After the Meetings
Fed Rate Cut Beneficiaries Fed Rate Cut Beneficiaries
Stocks that are expected to benefit from a Federal Reserve rate cut. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in Fed Rate Cut Beneficiaries, ranked from highest to lowest based on real-time market data. Stocks that are expected to benefit from a Federal Reserve rate cut. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in Fed Rate Cut Beneficiaries, ranked from highest to lowest based on real-time market data.
Unlock Now
U.S Tech Companies U.S Tech Companies
U.S leading technology companies with strong market presence, influential in their industries, and notable for robust innovation and profitability. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in U.S Tech Companies, ranked from highest to lowest based on real-time market data. U.S leading technology companies with strong market presence, influential in their industries, and notable for robust innovation and profitability. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in U.S Tech Companies, ranked from highest to lowest based on real-time market data.
Unlock Now
